Cannabidiol as a suggested candidate for treatment of autism spectrum disorder. POLEG S., GOLUBCHIK P., OFFEN D., WEIZMAN A. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 8, 89, 90-96. doi: 10.1016/j.pnpbp.2018.08.030 Abstract Autism Spectrum Disorder (ASD) is characterized by persistent deficits in social communication, restricted and repetitive patterns of behavior, interests, or activities and often intellectual disabilities. ASD has a number of prevalent co-morbidities, such as sleep disorders, attention deficit/hyperactivity disorder and epilepsy. No effective treatment for the core symptoms of ASD is currently available. There is increasing interest in cannabinoids, especially cannabidiol (CBD), as monotherapy or add-on treatment for the core symptoms and co-morbidities [...]
Lire la suiteTreatment of Fragile X Syndrome with Cannabidiol: A Case Series Study and Brief Review of the Literature Nicole Tartaglia, Marcel Bonn-Miller, and Randi Hagerman Cannabis and Cannabinoid Research, 2019, 4, 1 https://doi.org/10.1089/can.2018.0053 Abstract Fragile X syndrome (FXS) is an X-linked dominant disorder caused by a mutation in the fragile X mental retardation 1 gene. Cannabidiol (CBD) is an exogenous phytocannabinoid with therapeutic potential for individuals with anxiety, poor sleep, and cognitive deficits, as well as populations with endocannabinoid deficiencies, such as those who suffer from FXS. The objective of this study was to provide a brief narrative review of recent literature on endocannabinoids and FXS and [...]
Lire la suiteLong-Term Safety, Tolerability, and Efficacy of Cannabidiol in Children with Refractory Epilepsy: Results from an Expanded Access Program in the US Tristan T. Sands, Shahryar Rahdari, Michael S. Oldham, Eduardo Caminha Nunes, Nicole Tilton & Maria Roberta Cilio CNS Drugs, 2018 DOI : 10.1007/s40263-018-0589-2 Abstract Background : Purified cannabidiol is a new antiepileptic drug that has recently been approved for use in patients with Lennox–Gastaut and Dravet syndromes, but most published studies have not extended beyond 12–16 weeks. Objective : The objective of this study was to evaluate the long-term safety, tolerability, and efficacy of cannabidiol in children with epilepsy. Methods : Patients aged 1–17 years with refractory epilepsy were enrolled in an open-label [...]
Lire la suiteNeuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage Lorena Barataa, Luis Arruza, Maria-José Rodríguez, Esther Aleo, Eva Vierge, Enrique Criado, Elena Sobrino, Carlos Vargas, María Ceprián, Ana Gutiérrez-Rodríguez, William Hind, José Martínez-Orgado Neuropharmacology, 2018. https://doi.org/10.1016/j.neuropharm.2018.11.020 A B S T R A C T Objective : Hypothermia, the gold standard after a hypoxic-ischemic insult, is not beneficial in all treated newborns. Cannabidiol is neuroprotective in animal models of newborn hypoxic-ischemic encephalopathy. This study compared the relative efficacies of cannabidiol and hypothermia in newborn hypoxic-ischemic piglets and assessed whether addition of cannabidiol augments hypothermic neuroprotection. Methods : One day-old HI (carotid clamp and FiO2 10% for 20min) [...]
Lire la suiteCannabis Robert Hämmig, Ulrich W. Preuss und Michael Soyka January 2019 DOI: 10.1016/B978-3-437-23021-9.00009-6 Kernaussagen ● Die Cannabispflanze, welche die Menschheit seit Jahrtausenden begleitet, wird vi elfältig genutzt: ○ als Lieferant für Fasern zur Herstellung von Tüchern, Schnüren, Seilen und Papier, ○ als Nahrungsmittel (Samenkörner und Öl), ○ als Medizin für Mensch und Tier sowie als Genussmittel. ● Im 19. Jh. hielt Cannabis Einzug in die moderne westliche Medizin und wurde auch als „Freizeitdroge“ genutzt. Aus dieser Zeit stammen detaillierte phänomenologische Bes chreibungen der Effekte. Noch blieb aber der Wirkmechanismus völlig unklar. ● Die erste Hälfte des 20. Jh. ist das „dunkle Zeitalter“ des Cannabis, in dem das Fors chungsinteresse erlahmte. [...]
Lire la suiteREVIEW : Cannabidiol – Recent Advances Raphael Mechoulam, Maximilian Petersa, Eric Murillo-Rodriguez and Lumïr O. Hanus Chemistry and Biodiversity, 2007, 4, 1678-1692. The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non-psychoactive constituent of Cannabis, and to give a general overview. Special emphasis is laid on biochemical and pharmacological advances, and on novel mechanisms recently put forward, to shed light on some of the pharmacological effects that can possibly be rationalized through these mechanisms. The plethora of positive pharmacological effects observed with CBD make this compound a highly attractive therapeutic entity. Contents 1. Introduction 2. Mechanisms of Cannabidiol Action 2.1. Cannabidiol: an [...]
Lire la suiteStriking lung cancer response to self-administration of cannabidiol : A case report and literature review Josep Sulé-Suso, Nick A Watson, Daniel G van Pittius, Apurna Jegannathen SAGE Open Medical Case Reports, 2019, 7, 1-4. Abstract : In spite of new drugs, lung cancer is associated with a very poor prognosis. While targeted therapies are improving outcomes, it is not uncommon for many patients to have only a partial response, and relapse during follow-up. Thus, new drugs or reevaluation of existing therapies used to treat other non-malignant diseases (drug repurposing) are still needed. While this research both in vitro and in vivo is being carried [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4 Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suiteCannabidiol in Anxiety and Sleep : A Large Case Series SHANNON S., LEWIS N., LEE H., HUGHES S. The Permanente Journal, 2019, 23 Abstract CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a "high." A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical studies of [...]
Lire la suite